PI16 and esophageal squamous cell carcinoma: To explore the therapeutic potential of PI16 as a target, we knocked down PI16 expression in combination with cisplatin in an in vivo assay and found that knockdown of PI16 increased the therapeutic effect of cisplatin in mice with xenografts formed by ESCC cells and fibroblasts.